Yvette Fairfax: Wiskott-Aldrich Gene Therapy Changes Immunity, but Affordability May Determine Survival
Yvette Fairfax, Shareholder of KOELIS, shared a post on LinkedIn:
“The approval of the first gene therapy for Wiskott-Aldrich syndrome is a profound milestone for families facing a disorder linked to immune dysfunction, bleeding risk, and repeated infections.
For affected children, this kind of therapy is not just an incremental medical improvement. It has the potential to reduce hospital crises, improve stability, and reshape daily life in a much more fundamental way.But the controversy begins right after celebration.
Gene therapies often represent the best of science and the hardest realities of healthcare economics at the same time. A breakthrough can be medically transformative and still remain financially out of reach for families trapped in slow reimbursement systems or unequal access pathways.
In the U.S., UK, and Canada, rare-disease medicine keeps exposing the same structural tension: scientific innovation moves faster than fair access. If a one-time treatment can prevent years of suffering, complications, and repeated medical costs, waiting too long to fund it may be both unjust and inefficient.
Should public systems approve payment earlier for these therapies instead of forcing families through exhausting access battles first?”
Stay updated with Hemostasis Today.
-
Jun 7, 2026, 18:21Gulab Makwana: Complete Guide to Clotting Factors – Understanding the Coagulation System
-
Jun 7, 2026, 18:15Chuhan Dong: Presenting My Research on Antibody-Mediated RBC Clearance at Canadian Blood Services
-
Jun 7, 2026, 18:11Abdul Mannan: Pencil Cells in IDA – Why Most, but Not All Cases Show Them
-
Jun 7, 2026, 16:12Amr Mohamed: Common Types of Anemia
-
Jun 7, 2026, 15:50Venkateshwarlu Bairi: AVEVA Hyderabad Supports Children Living with Thalassemia and Sickle Cell Conditions
-
Jun 7, 2026, 15:48José Antonio García Erce: Hemochromatosis and Blood Donation
-
Jun 7, 2026, 15:29Marc Scherlinger: Uncovering the Immuno-Inflammatory Functions of Platelets at EULAR 2026
-
Jun 7, 2026, 15:18Huyen Nguyen: Highlights from the NCCN Cancer-Associated Venous Thromboembolic Disease Guidelines
-
Jun 7, 2026, 14:35Erica Wood: WHO Launches Landmark Action Framework to Secure Safe and Equitable Blood Supply Worldwide